Lowering the approval hurdles in Dimerix's (ASX:DXB) Phase 3 trial is expected to boost the success, value, and appeal of the company's kidney failure therapy, DMX-200, to potential US partners, according to a Feb. 9 note by Euroz Hartleys.
In January, the company said findings from the US Food and Drug Administration-funded Project Parasol showed that reduced protein in urine lowers the risk of kidney disease progression.
Dimerix requested a meeting with the US FDA to agree on the appropriate protein in urine endpoints for DMX-200 in the Action3 Phase 3 trial, which aims to test the medication in patients with focal segmental glomerulosclerosis, a form of kidney disease.
Euroz believes that as the FDA already approved the design of the company's Phase 3, any modifications during the meeting are optional and offer potential upside.
The firm maintained DXB's speculative buy rating and its AU$1.06 price target.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。